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418 | Anal. Methods, 2016, 8, 418–424t protein-based assays for high-
throughput functional characterization and ligand-
binding studies of biotin protein ligase†
Samuel P. Askin, Thomas E. H. Bond and Patrick M. Schaeffer*
In E. coli and other prokaryotes such as Staphylococcus aureus, and Mycobacterium tuberculosis, biotin
protein ligase (BirA) is an emerging drug target as it is the sole enzyme capable of biotin transfer onto
the BCCP subunit of ACC. There is currently a gap in simple yet efficient assays for rapidly identifying
and characterising inhibitors targeting BirA. We present for the first time the development and validation
of a simple and reliable DSF-GTP assay for the high-throughput screening of BirA:ligand interactions
using a new GFP-tagged BirA of E. coli. In addition, we developed a new GFP-based biotinylation activity
assay taking advantage of a GFP tethered with an AviTag. The data obtained with these assays revealed
new insights into how the binding of individual or combinations of ligands affect the overall thermal
stability and affinity of BirA. The DSF-GTP assay has a Z0 value of 0.785 that makes it an excellent tool for
future high-throughput screening of inhibitory compounds.Introduction
Drug discovery is a rapidly expanding and diversifying eld.
This is in part due to the need to identify alternatives to current
therapeutics which are failing as a result of emerging global
antibiotic resistance by prevalent bacteria. Strategies to combat
antibiotic resistance centre upon the identication of novel
compounds to inhibit already established drug targets, identi-
cation of new drug targets or target pathways, or a combina-
tion of the two. In identifying novel targets in a disease, there is
a necessity to comprehensively characterize the target. This
allows screening in optimal conditions for monitoring activity
or stability of the target as well as a prior, in-depth under-
standing of specic ligand interactions of the target.
A critical pathway to survival of both eukaryotes and
prokaryotes that is targeted in new therapies is fatty acid
biosynthesis.1 In E. coli, fatty acid biosynthesis reactions are
processed by individual enzymes, following the type II fatty acid
synthase pathway. The fatty acid biosynthesis pathway in E. coli
is well characterized and begins via the catalysis of the
conversion of acetyl-CoA to malonyl-CoA by the acetyl-coA
carboxylase (ACC). Critical to this process is the transfer of
biotin to the biotin carboxyl carrier protein (BCCP) subunit of
ACC. ACC, and hence the entire fatty acid biosynthesis pathway,k University, DB21, James Cook Drive,
atrick.schaeffer@jcu.edu.au; Fax: +61 7
tion (ESI) available. See DOI:is therefore dependent on the synthesis, concentration, and
downstream processing of biotin.2,3
In E. coli and other prokaryotes such as Staphylococcus aureus,
and Mycobacterium tuberculosis, biotin protein ligase (BirA) is an
emerging drug target as it is the sole enzyme capable of biotin
transfer onto the BCCP subunit of ACC.4–6 Further to this, the
BirA of E. coli also regulates expression of bio genes and subse-
quently biotin synthesis through binding to the biotin operator
(bioO), a 40 bp inverted repeat that overlaps and controls both
biotin operon promoters.7,8 The apoform of BirA (apoBirA) binds
to biotin and ATP which are converted to the adenylated inter-
mediate biotinyl-50-AMP (bio-50-AMP) with the release of PPi.9 The
bio-50-AMP:BirA complex has been described as the holoform of
the protein (holoBirA). Biotin is subsequently transferred by
holoBirA onto BCCP. The formation of an amide bond between
the bio-50-AMP and a single lysine residue of the BCCP subunit
allows for downstream processing of fatty acid chain extension to
then take place. The holoBirA also acts as a co-repressor through
its binding to bioO.7,10–16
The interactions between BirA and its ligands have been
extensively studied via numerous methods. However, the
development of high-throughput (HT) assays capable of
screening large libraries of inhibitors in a drug screening
context has been limited.17 The emergence of technologies such
as differential scanning uorimetry (DSF), led by the widely
adopted Thermouor assay,18 has been enterprizing in the eld
of drug discovery and protein characterization for their ability
to prole thousands of conditions simultaneously in small
volumes. Recently, a new DSF platform based on the screening
of GFP-tagged proteins (DSF-GTP) was developed to prole
protein thermal stability in high-throughput (HT).19–21 This newThis journal is © The Royal Society of Chemistry 2016
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View Article Onlineplatform does not require the addition of a solvatochromic dye
to the reaction thus eliminating the possibility of interferences
with protein–ligand interactions. DSF-GTP has also the added
advantage that it can be performed in the presence of additional
proteins.
Here, we describe for the rst time the development and
validation of a DSF-GTP assay for the HT screening of Bir-
A:ligand interactions using a new GFP-tagged BirA of E. coli. In
addition, taking advantage of GFP and the GFP-tagged BirA we
developed a suite of new sensitive uorescence-based secondary
screening and activity assays for BirA in preparation for future
screening of inhibitory compounds and to decipher their
mechanisms of action.Fig. 1 GFP-based biotinylation activity assay. (A) Schematic repre-
sentation of the GFP-based biotinylation activity assay workflow.
Recombinant GFP-AviTag (30 mM) is reacted at room temperature for
1 h with recombinant BirA-GFP (0.3 mM) in the presence of ATP (2.5 mM),
biotin (0.5mM) andMgCl2 (1mM) for biotinylation of the AviTag in 25mM
Tris–HCl (pH 8). The biotinylated GFP-AviTag (GFP-AviTag-bio) is then
bound to a 1.5 ml spin column containing Ni-affinity resin to eliminate
excess biotin. The bound GFP-AviTag-bio is eluted in buffer containing
200 mM imidazole by centrifuging at 1000g. Following elution, GFP-
AviTag-bio is incubated with excess streptavidin (Stv) for 15 min at room
temperature and subjected to SDS-PAGE. Samples are loaded without
a heat-denaturation step to allow for direct in-gel fluorescence detectionMaterials and methods
Cloning, expression and purication of proteins
The GFP-AviTag vector (pSA241) was cloned by digesting the
GFP-HA coding vector pIM057 22 and the AviTag vector
pSA236 23 with KpnI, and dephosphorylation of pSA236 over-
hangs to prevent vector reclosing. The GFP sequence from
pIM057 was then ligated into the digested pSA236 to produce
pSA241. The direction of insert ligation was checked by colony
PCR following transformation into E. coli DH12S cells.
BirA and BirA-GFP expression vectors were derived from
pIM022 (pETc-GK-GFP).19 The BirA coding sequence was
amplied from E. coli DH12S genomic DNA using the primers
psJCU319: 50-AAAAAACTTAAGAAGGATAACACCGTGCCACTG-30
and psJCU320: 50-AAAAAAGCTAGCTTTTTCTGCACTACG-
CAGGG-30. The PCR product was digested with NheI and ligated
into an EcoRV and NheI digested pIM022 to produce p6HIS-
BirA-GFP (pSA239). The plasmid pSA239 was digested with NheI
and an end-lling reaction performed to introduce a stop codon
between the BirA and GFP coding regions to form p6HIS-BirA
(pSA267) using a previously described method.19
BirA was expressed and puried as previously described.23
GFP-AviTag was expressed and puried similarly to a previously
described procedure.24 BirA-GFP was expressed in E. coli Single
Step KRX competent cells (Promega). E. coli Single Step KRX
cells were transformed with pSA239 and grown in LB media
supplemented with ampicillin (100 mg ml1) overnight at 37 C,
shaken at 200 rpm. 100 ml cultures of LB supplemented with
ampicillin (100 mg ml1) were then inoculated and incubated at
37 C with shaking at 200 rpm until the optical density (OD600)
reached 1, at which time expression of BirA-GFP was induced
with 0.1% (nal) rhamnose. Temperature was then reduced to
16 C and incubation with shaking continued until OD reached
3–5. Cells were harvested, lysed and puried by Ni-affinity
chromatography as previously described,24 however cell pellets
were resuspended in BirA buffer (25 mM Tris (pH 8), 100 mM
NaCl, 5% v/v glycerol). BirA-GFP and BirA purity was assessed by
SDS-PAGE and quantication performed by Bradford assay.of GFP. Fluorescent proteins are analysed by direct UV-irradiation of the
gel and integration of GFP fluorescence. (B) Detection of GFP-AviTag
biotinylation by SDS-PAGE and Stv-induced band-shift analysis. Bio-
tinylation reactions were performed and processed as described in
Fig. 1A. Control reactions were performed in the absence of BirA-GFP
and Stv, or by saturating Stv with excess biotin (*) as indicated.GFP-based biotinylation activity assay
The biotinylation activity of BirA-GFP was determined analo-
gously to a recently published method.23 Biotinylation of GFP-This journal is © The Royal Society of Chemistry 2016AviTag was performed in 50 ml reactions containing 0.3 mMBirA-
GFP, 0.5 mM biotin, 2.5 mM ATP, 1 mMMgCl2 and 30 mM GFP-
AviTag in 25 mM Tris (pH 8.0). Control reactions without BirA-
GFP were performed in parallel. Reactions were incubated at
room temperature for 1 h. Following incubation, biotin was
removed from the reactions by Ni-affinity purication using
Pronity IMAC nickel resin (Biorad) and 1.5 ml spin columns.
Reactions were bound to 50 ml pre-equilibrated nickel resin
slurry for 5 min at 4 C, then passed through the resin twice by
centrifugation at 1000  g for 1 min at 4 C. The resin was
washed twice with 500 ml of 25 mM Tris (pH 8.0) supplemented
with 5% glycerol and 150 mMNaCl by centrifugation at 1000 g
for 1min at 4 C. The proteins were eluted from the spin columns
with 50 ml of the same buffer supplemented with 200 mM
imidazole and centrifugation at 1000  g for 1 min at 4 C
following 5 min incubation at 4 C. The eluate was then passed
a second time through the same spin column as for rst elution.
Following purication, 7.5 ml of protein elution from spin
column (see above) with or without BirA-GFP were incubated
with 0.75 ml Stv (streptavidin, 5 mg ml1, Invitrogen) at room
temperature for 15 min in duplicate. Reactions were then sub-
jected to SDS-PAGE and the uorescence of GFP-AviTag ana-
lysed by integration of protein bands (ImageJ, NIH, USA) to
determine the extent of biotinylation through binding to Stv.
Control reactions were performed similarly by omitting BirA-
GFP or Stv as indicated (cf. Fig. 1A). An additional control
reaction was performed including the addition of competing
biotin (0.3 mM) to Stv prior to addition to the reacted GFP-
AviTag. All control reactions were processed in identical fashionAnal. Methods, 2016, 8, 418–424 | 419
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View Article Onlinefor comparison to account for protein losses occurred during
purication and reaction steps and for normalization. Three
independent experiments were performed.
Electrophoretic mobility shi assay
Oligonucleotides psJCU349 50-TAATCGACTTGTAAACCAAATT-
GAAAAGATTTAGGTTTACAAGTCTACAC-30 and psJCU350 50-
GTGTAGACTTGTAAACCTAAATCTTTTCAATTTGGTTTACAAGTC-
GATTA-30 (400 mM in 25 mM Tris, 50 mM NaCl) comprising the
bioO 40 bp sequence with 5 bp anking sequences (underlined)
were mixed together and annealed by heating at 80 C for 2 min
followed by slow cooling to room temperature (rt).
All reactions contained 1 mM BirA-GFP, 1 mM bioO, 10 mM
Tris (pH 8), 0.83% glycerol and 50 mM NaCl. In addition to
these components some reactions were spiked with 0.83 mM
biotin, 0.83 mM ATP and MgCl2, and combinations thereof as
indicated in Fig. 2A. All reactions were incubated at rt for 15
min, then analysed by agarose gel electrophoresis followed by
staining with GelRed and integration of uorescent bands
(ImageJ, NIH, USA).
Size exclusion chromatography
For SEC analysis of apo- and holoBirA-GFP, BirA-GFP (100 ml at
20 mM in BirA buffer) was combined with 100 ml of either : 25
mM Tris (pH 8) or 25 mM Tris (pH 8) supplemented with 2 mM
of biotin, ATP and MgCl2. For SEC in the presence of bioO, BirA-
GFP was rst mixed with bioO (100 ml at 20 mM each in BirA
buffer) and incubated for 10min at rt prior tomixing with 100 mlFig. 2 DNA-binding activity and dimerization of BirA-GFP and BirA. (A)
Determination of bioO-binding to BirA-GFP by EMSA. BirA-GFP (1 mM)
was reacted with bioO (0.5 mM) in the presence of 1 mM biotin, 1 mM
ATP or 1 mM biotin, 1 mM ATP and 1 mM MgCl2 for 10 min at rt.
Reactions were then analysed by agarose gel electrophoresis and
GelRed staining. The positions of free bioO probe (C) and shifted bands
are indicated. Identical experiments were also performed with BirA
(cf. ESI Fig. S1†). (B) Top: SEC analysis of BirA-GFP. BirA-GFP (10 mM)
was injected either alone, in the presence of 1 mM biotin, 1 mM ATP
and 1mMMgCl2, or in the presence of bioO (10 mM), 1 mM biotin, 1 mM
ATP and 1 mM MgCl2. The proteins were detected through the fluo-
rescence of the GFP domain of BirA-GFP. Bottom: SEC analysis of BirA.
Reactions were as described for BirA-GFP, however BirA and bioO
were present at 100 mM each and protein peaks were determined by
UV absorption.
420 | Anal. Methods, 2016, 8, 418–424of 25 mM Tris (pH 8) supplemented with 2 mM of biotin, ATP
and MgCl2. All reactions were incubated for 10 min at rt. The
reactions were then injected in a Superdex 200 10/300 GL
column (GE Lifesciences) equilibrated in BirA buffer using
a Biologic Duoow Chromatography System (Biorad) with
a owrate of 0.25 ml min1. Following fractionation of BirA-
GFP, 200 ml of each fraction was analysed using a uorescence
plate reader (Victor 3VWallac 1420, Perkin-Elmer) set to 355 nm
excitation/535 nm emission.
SEC analysis of BirA was performed as described above,
however the concentrations of BirA and bioO were increased 10-
fold in all cases. UV absorbance was used to determine the
peaks and quaternary structure of BirA in each of the condi-
tions. Fractions containing the peak expected to be the bio-
O:BirA dimer (10 ml) were also analysed by SDS-PAGE followed
by Coomassie Blue staining (cf. ESI Fig. S2†).DSF-GTP assay
All reactions (50 ml) containing 3 mM BirA-GFP were performed
in a reaction buffer consisting of 15 mM Tris–HCl (pH 8), 10
mM NaCl and 0.5% (v/v) glycerol. Ligands and additives were
added to the reaction buffer as indicated in the following
sections. All reactions were equilibrated for 10 min at rt prior
being subjected to melt-curve analysis using a real-time thermal
cycler (IQ5 iCycler, Bio-Rad). Temperature range was set from
35–85 C, increasing in 0.5 C increments every 30 s. Data was
analysed as previously described.20 All reactions were performed
at least in duplicates.
Biotin and ATP dependence. To determine the effect of
biotin on the Tm of BirA-GFP, reactions were performed with
increasing concentrations of biotin ranging from 500 nM to 1
mM as indicated in Fig. 3. To determine the combined effects of
ATP and biotin, reactions were performed with increasing
concentrations of both species ranging from 500 nM to 1 mM
and 1 mM MgCl2. To determine the effect of ATP on the Tm of
biotin-bound BirA-GFP, reactions were performed with
increasing concentrations of ATP ranging from 500 nM to 1
mM, 1 mM biotin and 1 mM MgCl2.
Nucleotide specicity. To determine the effect of different
nucleotides on the Tm of BirA-GFP, reactions were performed in
the presence of 1 mM of either ATP, CTP, UTP or GTP and 1 mM
MgCl2. To determine the effect of different nucleotides on the
Tm of biotin-bound BirA-GFP, reactions were performed as
above in the presence of 1 mM biotin. All nucleotide stocks were
buffered (pH 8).Results and Discussion
Biotin transfer activity of BirA and BirA-GFP
The production of a functional GFP-tagged BirA (BirA-GFP) was
required for the DSF-GTP assay. First, the biotinylation activity
of BirA-GFP was determined with a new GFP-based biotinylation
activity assay to assess whether GFP-tagging of BirA was not
detrimental to its activity. The new assay relies on complex
formation between a biotinylated GFP containing the AviTag
biotinylation sequence (GLNDIFEAQKIEWHE)25–28 andThis journal is © The Royal Society of Chemistry 2016
Fig. 3 Thermal stability of BirA-GFP by DSF-GTP. (A) DSF-GTP melt-curves (d(RFU)/dT) demonstrating the effect of increasing biotin
concentrations on BirA-GFP thermal stability. BirA-GFP (3 mM)was reactedwith increasing concentrations of biotin ranging from 500 nM to 1mM
for 10 min at rt prior to analysis by DSF-GTP. (B) The concentration dependence of biotin on Tm of BirA-GFP. DTm values were calculated by
subtracting Tm of apoBirA-GFP from the Tm obtained in presence of increasing [biotin]. (C) Nucleotide specificity of BirA-GFP. Effect of different
nucleotides (1 mM) as indicated on the Tm of BirA-GFP in the presence or absence of 1 mM biotin and MgCl2. BirA-GFP was reacted with each
nucleotide (with or without biotin/MgCl2). (D) Comparison of the effect of simultaneous increase of [biotin], [ATP] and [MgCl2] (red squares) vs.
independent increase of [ATP] in the presence of 1 mM biotin and MgCl2 (open triangles) on BirA-GFP Tm. Reactions of BirA-GFP with increasing
[biotin] (black circles) were also performed for comparison. For all experiments, error bars represent standard deviations (n ¼ 3).
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View Article Onlinea streptavidin (Stv) probe23 resulting in an electrophoretic
mobility shi of the complex detectable by SDS-PAGE (Fig. 1A).
The GFP-based biotinylation activity assay is identical in prin-
ciple to our recent ‘in-gel biotin–protein conjugate detection
assay’.23 Here, a new AviTag-labelled GFP (GFP-AviTag) was
developed and used as substrate for BirA-GFP. GFP-AviTag
(30 mM) was biotinylated by BirA-GFP at room temperature (rt)
for 1 h. Aer removal of excess biotin the biotinylated GFP-
AviTag was bound to Stv and analysed by SDS-PAGE. For this
assay it is important to not heat-denature the samples before
loading onto the polyacrylamide gel to avoid loss of the GFP
uorophore. The biotinylation activity assay is not intended for
measuring enzyme kinetics but it is a useful rapid end-point
assay and has the potential to be applied for the identication
of biotinylation inhibitors.
In-gel uorescence quantitation of the reacted GFP-AviTag
showed that BirA-GFP was able to biotinylate 96% of the
protein in 1 h at rt (Fig. 1B). Abolition of biotinylated GFP-Avi-
Tag:Stv complex formation by the addition of 0.3 mM biotin to
Stv prior addition of GFP-AviTag (Fig. 1B, far right lane)
conrmed that the GFP-shi observed was the result of StvThis journal is © The Royal Society of Chemistry 2016binding. Faint higher order bands were visible in those wells
that Stv was included. These were due to a protease contami-
nation present in the commercial Stv sample (data not shown).
However the level of proteolysis was negligible in the context of
determining the activity of BirA-GFP and did not affect quanti-
tation. The level of biotinylation obtained with BirA-GFP and
the GFP-AviTag corresponds well to in vitro biotinylation activity
levels previously reported by us and others for a variety of tagged
and untagged BirA.23,29 Indeed, BirA and BirA-GFP yielded
almost identical levels of biotinylated AviTag probes in the same
conditions23 demonstrating that the tagging of BirA does not
signicantly affect its activity.Dimerization and DNA-binding activity of BirA and BirA-GFP
A 50 bp double strand oligonucleotide consisting of the 40 bp
bioO sequence anked at either end by 5 bp of natural chro-
mosomal sequences was used to test the DNA-binding activities
of BirA (cf. ESI Fig. S1†) and BirA-GFP (Fig. 2A). The binding of
BirA and BirA-GFP to bioO was analysed by EMSA demon-
strating that the presence of the GFP did not signicantly affectAnal. Methods, 2016, 8, 418–424 | 421
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View Article OnlineBirA DNA-binding activity. Previous studies have shown that
holoBirA binds with the greatest affinity to bioO – i.e. in the
presence of the co-repressor bio-50-AMP.7,30,31 The biotin-bound
BirA and apoBirA bind cooperatively to bioO with 10-fold and
50-fold lower affinity respectively than holoBirA,31 and this
was also evident with our GFP-tagged species in our high-salt
conditions (Fig. 2A). The same difference in affinity was also
conrmed with the BirA species (cf. ESI Fig. S1†).
The quaternary structure of BirA and BirA-GFP was then
analysed by size exclusion chromatography (SEC). BirA
(injected at 100 mM initial concentration) was detected by UV
absorption whereas BirA-GFP could be analysed by uorimetry
at a ten-fold lower concentration (i.e. 10 mM initial concen-
tration). Both proteins remained in a monomeric form in their
apoforms. Previous data have shown that apoBirA and the
biotin-bound form can dimerize in low salt conditions at mM
concentrations.31 These complexes would therefore not be
observed in our high-salt SEC conditions. A slight shi was
observed for both holoBirA and holoBirA-GFP (Fig. 2B). These
shis in elution suggest a dramatic change in conformation of
the proteins or a fast exchanging dimer form in our SEC
conditions. Previous studies indicate that dimerization of
holoBirA is inuenced by ionic strength with reported KD
values for dimerization of 1 and 10 mM in low- and high-salt
respectively.30,31 As expected, a dramatic shi in elution was
observed for both holoBirA and holoBirA-GFP upon addition
of bioO reecting their dimer formation and bioO binding
(Fig. 2B and C; ESI Fig. S2†). The high sensitivity of the uo-
rimetric SEC assay compared to UV detection, makes it an
attractive secondary assay for the identication of molecules
capable of interfering with dimer formation and DNA-binding
activity of BirA-GFP.HT characterization of BirA-GFP by DSF-GTP
The structural and functional characterization of BirA-GFP in
the previous sections demonstrated that the tethering of GFP
has no effect on BirA activity. The use of DSF-GTP requires that
a transition in the melting curve can be observed corresponding
to the BirA domain unfolding before complete loss of GFP
uorescence at80 C (Fig. 3A). We identied a clear transition
in the melting curve of BirA-GFP and validated the assay with
increasing concentrations of biotin for which increasing tran-
sition midpoint (Tm) values could be recorded as illustrated in
Fig. 3A. For this, BirA-GFP (3 mM) was reacted with increasing
concentrations of biotin ranging from 488 nM–1 mM for 10 min
at rt, prior to determination of Tm by DSF-GTP. Fig. 3B illus-
trates the perfect correlation between BirA-GFP thermal stability
and biotin concentration obtained from data presented in
Fig. 3A. The thermal stability of BirA-GFP (41 C) increased
progressively by up to 12.5 C in the presence of 1 mM biotin
(Fig. 3A and B). A best-t trendline was obtained with a R-square
value > 0.99 reecting the excellent reproducibility of the assay.
The quality of the new HT DSF-GTP assay for BirA was further
assessed by Z0-factor32 determination which yielded an excellent
Z0 value of 0.785 (n ¼ 96).422 | Anal. Methods, 2016, 8, 418–424BirA-GFP was then proled for nucleotide specicity both
alone and in combination with biotin and MgCl2. When the
effect of nucleotides alone was investigated, the Tm of BirA-GFP
increased only by 2 C with 1 mM ATP. GTP was the most
stabilizing2.9 C, and CTP and UTP the least stabilizing <2 C.
Interestingly, the Tm of BirA-GFP was increased by12 C in the
presence of 1 mM biotin, and by 20.5 C when reacted with
both 1 mM biotin and ATP (i.e. leading to formation of bio-50-
AMP; Fig. 3C). We did not observe any cumulative stabilizing
effects for UTP, CTP or GTP that could suggest the formation of
higher affinity intermediates with these species in the presence
of biotin. The large increase in Tm of BirA-GFP upon binding of
both ATP and biotin suggesting the formation of bio-50-AMP is
well supported by the recently reported KD of 50 pM for the
holocomplex.33 Our data correlates well with the sequential
binding of biotin and ATP by BirA, with biotin binding rst
leading to the formation of a specic ATP binding site.13–15,34–36
This site is largely non-existent and nonspecic prior to biotin
binding. A disordered loop of the apoBirA structure (i.e. resi-
dues 212–233) known as the adenylate binding loop (ABL) is
involved in ATP binding.36 The ABL becomes ordered upon
binding of ATP by BirA and folds over it.15
BirA has previously been shown to have very low in vitro
biotinylation activity with CTP (10%) and GTP (5%).17 Our
data suggests that GTP binds marginally better to the non-
specic binding pocket of apoBirA-GFP in the absence of biotin.
Nevertheless, considering the very low affinity of BirA for all
nucleotides in the absence of biotin (Fig. 3C) and the total
absence of cumulative stabilisation with GTP, CTP and UTP in
the presence of biotin, it is unlikely that any of these nucleo-
tides could lead to formation of the ABL in the absence of
biotin. The low biotinylation activity of BirA observed in the
presence of high concentrations of CTP or GTP17 could therefore
only be explained by reaction of BirA-bound biotin with GTP or
CTP without ABL formation. To our knowledge, this is the rst
study of the sequential binding of different nucleotides and
their specicity to the ATP binding site using DSF.
We have previously been able to estimate the apparent
binding parameters (Kobs) of glycerol kinase and Tus for their
respective ligands with DSF-GTP in conditions of [ligand] >
[protein] using a simple graphical method. In both cases, the Kobs
were in agreement with the dissociation constants (KD) obtained
with alternative quantitative methods.20,21 Kobs is dened as the
concentration of ligand at which the titration curve trendline for
a given ligand (Fig. 3D) intercepts with log[ligand]-axis at the Tm
of the unliganded protein. The thermal slopes are identical
within a protein for different ligands since they are determined
by the unfolding enthalpy.37 It is therefore important to note that
Kobs is not directly comparable to KD although changes in Kobs
will be proportional to changes in KD. Using our simple graphical
method we obtained a Kobs of 231 nM (ESI Table S1†) which was
5-fold higher than the previously reported KD of 45 nM38 –
similar to the range of endogenous biotin concentration in E. coli.
The difference observed between our Kobs and the previously re-
ported KD may potentially be due to the different conditions and
pH in our study as well as temperature effects and possible steric
hindrances from the GFP.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineNext, we investigated the combined effect of ATP and biotin
leading to bio-50-AMP production on BirA-GFP's thermal
stability (Fig. 3D). Based on the KD of 50 pM that has recently
been reported for the holoBirA complex, we expected that
a sharp increase in BirA-GFP thermal stability would occur upon
bio-50-AMP production resulting in a sigmoidal titration curve
around ligand concentrations corresponding to the BirA-GFP
concentration used in the reaction as well as the presence of two
peaks corresponding to the unbound and bound protein form.
For this, two different experimental setups were performed: (a)
the effects of serial dilutions of an equimolar solution of ATP
and biotin were analysed on BirA-GFP Tm; and (b) the concen-
tration of biotin was kept constant and the effects of serial
dilutions of ATP were analysed. When [biotin] was kept constant
(1 mM) and [ATP] was varied, the lowest concentration of ATP
tested (500 nM) was not stabilizing BirA-GFP beyond the effect
of 1 mM biotin (cf. Fig. 3D; black circles). A very small sigmoi-
dicity was observed at 2 mM ATP followed by a steady increase
in BirA-GFP Tm with higher ATP concentrations (Fig. 3D). When
both [biotin] and [ATP] were increased simultaneously (Fig. 3D;
red squares), two distinct BirA-GFP Tm peaks were observed
between 1.9–7.8 mM immediately suggesting a KD < 10 nM as
expected. One Tm peak corresponded to the effect of biotin only
(Fig. 3D; black circles) and the other Tm peak that was sharply
increased – i.e. converging towards the curve obtained for xed
[biotin] with increasing [ATP] (Fig. 3D; open triangles) – most
likely corresponded to the holoBirA-GFP complex. When the
concentration of ligands was >8 mM, only the higher Tm peaks
were observed reecting the curve obtained for xed [biotin]
with increasing [ATP] (Fig. 3D; cf. open triangles with red
squares). As the increase in BirA-GFP Tm is very sharp >1 mM
biotin and ATP – i.e. much more than would be expected for
merely additive effects of biotin and ATP – we can conclude that
the very sharp increase in BirA-GFP Tm reects formation of the
tighter bio-50-AMP:BirA-GFP complex. It also suggests that
binding of biotin signicantly increases the affinity for ATP by
several orders of magnitude through formation of the biotin-
induced ATP binding site and ABL.
The titration curve obtained with biotin (Fig. 3D; black
circles) has a much steeper slope than the ones obtained in the
presence of both ATP and biotin (Fig. 3D; open triangles and red
squares) revealing that the biotin-bound BirA-GFP form might
have a signicantly smaller enthalpy of unfolding compared to
the ATP and biotin form. This argument has to be taken with
caution due to the complexity of the system. Indeed, formation
and dissociation of the bio-50-AMP adduct which binds much
tighter than biotin and ATP to BirA-GFP, might be limiting steps
inuencing the slope of these titration curves. Nevertheless, due
to the linearity of the titration curves suggesting 100% conver-
sion of ATP and biotin into bio-50-AMP (Fig. 3D and ESI Table
S1†) we decided to determine the Kobs values from the two
different experimental setups. Here, a Kobs of 3.3 pM was ob-
tained in increasing [biotin] and [ATP] which was similar to the
Kobs of 7.4 pM in constant [biotin] and increasing [ATP]. These
Kobs values reected quite well the tight affinity and KD of BirA
with the bio-50-AMP adduct (i.e. 50 pM in 200 mMKCl and pH 8)
reported by Eginton et al.33 although our reactions wereThis journal is © The Royal Society of Chemistry 2016performed with the natural substrates ATP and biotin, in low
salt and slightly higher pH conditions.
To our knowledge this is the rst time that the biotin-
induced conformational changes leading to ATP binding and
bio-50-AMP:BirA-GFP complex could be analysed by DSF in such
depth. Overall the combined analyses of nucleotide specicity
and ligand concentration dependence demonstrate the versa-
tility and breadth of information that can be easily and rapidly
gained using DSF-GTP for BirA-GFP characterization.Conclusions
In this study, we demonstrate the utility and high quality of
a new HT DSF-GTP assay for the high-throughput character-
ization of BirA (Z0 ¼ 0.785), an emerging drug target for anti-
biotic development. BirA could be fused to a C-terminal GFP
without the requirement for any further solubility tags for high-
level production of soluble and functional proteins. BirA-GFP
was fully functional when compared to BirA and was able to
biotinylate 96% of GFP-AviTag in 1 h at rt. Our results ob-
tained with the different natural BirA ligands reected well the
previously known properties of BirA as well as revealed new
insights into how its binding to individual or combinations of
ligands affects the overall thermal stability of the protein. With
the validation of E. coli BirA-GFP in the new DSF-GTP, SEC,
EMSA and GFP-based biotinylation activity assays now at hand,
the subject of future work will be to apply this suite of assays for
HT screening and identication of BirA inhibitors and to deci-
pher their mechanisms of action and structure activity rela-
tionships. It is expected that our workow will be adaptable to
other bacterial BirA orthologs as well as the human hol-
ocarboxylase synthetase and that it will signicantly streamline
their target characterization to screening processes by reducing
time and cost.Conflict of interest
The authors declare that they have no conict of interest.References
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